SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-040352
Filing Date
2024-04-02
Accepted
2024-04-02 17:12:17
Documents
1
Period of Report
2024-04-01

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 3219
  Complete submission text file 0000950170-24-040352.txt   4640
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1 CRANBERRY HILL SUITE 200 LEXINGTON MA 02421
Business Address
Lees-Rolfe Garth (Reporting) CIK: 0002017374 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 24815507